These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11152377)

  • 1. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A; Gyönös I; Magyar J; Bányász T; Nánási PP; Spedding M; Szénási G
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dofetilide and EGIS-7229, an antiarrhythmic agent possessing class III, IV, and IB activities, on myocardial refractoriness in hyperkalemia, hypokalemia, and during beta-adrenergic activation in the rabbit papillary muscle in vitro.
    Kovács A; Szénási G
    J Pharmacol Sci; 2006 Apr; 100(4):303-9. PubMed ID: 16603803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499.
    Baskin EP; Lynch JJ
    J Cardiovasc Pharmacol; 1994 Aug; 24(2):199-208. PubMed ID: 7526051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-adrenoceptor activation plays a role in the reverse rate-dependency of effective refractory period lengthening by dofetilide in the guinea-pig atrium, in vitro.
    Kovács A; Magyar J; Bányász T; Nánási PP; Szénási G
    Br J Pharmacol; 2003 Aug; 139(8):1555-63. PubMed ID: 12922944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues.
    Pankucsi C; Bányász T; Magyar J; Gyönös I; Kovács A; Varró A; Szénási G; Nánási PP
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):398-405. PubMed ID: 9089672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
    Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle.
    Yang T; Tande PM; Refsum H
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):889-94. PubMed ID: 1282590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGIS-7229, the new combined class III antiarrhythmic agent: lack of EAD inducing effect.
    Bányász T; Magyar J; Varró A; Kovács A; Gyönös I; Szénási G; Nánási PP
    Gen Pharmacol; 1999 Mar; 32(3):329-33. PubMed ID: 10211587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle.
    Marschang H; Beyer T; Karolyi L; Kübler W; Brachmann J
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):573-83. PubMed ID: 10410827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
    Baczkó I; El-Reyani NE; Farkas A; Virág L; Iost N; Leprán I; Mátyus P; Varró A; Papp JG
    Eur J Pharmacol; 2000 Sep; 404(1-2):181-90. PubMed ID: 10980278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents.
    Lynch JJ; Baskin EP; Nutt EM; Guinosso PJ; Hamill T; Salata JJ; Woods CM
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):336-40. PubMed ID: 7752661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
    Gwilt M; Blackburn KJ; Burges RA; Higgins AJ; Milne AA; Solca AM
    Eur J Pharmacol; 1992 May; 215(2-3):137-44. PubMed ID: 1396982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle.
    Yang T; Tande PM; Lathrop DA; Refsum H
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):429-36. PubMed ID: 1520650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KCB-328: a novel class III antiarrhythmic agent with little reverse frequency dependence in isolated guinea pig myocardium.
    Lee K; Lee JY; Kim HY; Kwon LS; Shin HS; Tanabe S; Kozono T; Park SD; Chung YS
    J Cardiovasc Pharmacol; 1998 Apr; 31(4):609-17. PubMed ID: 9554812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
    Hashimoto N; Yamashita T; Tsuruzoe N
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle.
    Baskin EP; Serik CM; Wallace AA; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):406-14. PubMed ID: 1720841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular electrophysiologic effect of a new amiodarone like antiarrhythmic drug GYKI 16638 in undiseased human ventricular muscle: comparison with sotalol and mexiletine.
    Opincariu M; Varró A; Iost N; Virág L; Hála O; Szolnoki J; Szécsi J; Bogáts G; Szenohradszky P; Mátyus P; Papp JG
    Curr Med Chem; 2002 Jan; 9(1):41-6. PubMed ID: 11860346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.
    Chorro FJ; Sanchis J
    Pacing Clin Electrophysiol; 2004 Mar; 27(3):327-32. PubMed ID: 15009858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B.
    Schreieck J; Wang Y; Gjini V; Korth M; Zrenner B; Schömig A; Schmitt C
    J Cardiovasc Electrophysiol; 1997 Dec; 8(12):1420-30. PubMed ID: 9436780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.